CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis
Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, randomized, double-blinded, placebo-controlled trial in patients, ≥12
years of age who weigh ≥40 kg, and are diagnosed with moderate-to-severe AD.